Transition From Research to Disclosure in Human Genetics

Sponsor
M.D. Anderson Cancer Center (Other)
Overall Status
Completed
CT.gov ID
NCT00505466
Collaborator
(none)
577
1
273.1
2.1

Study Details

Study Description

Brief Summary

The goal of this study is to design a means of providing research families, from diverse geographical locations, the chance to receive genetic testing after having been educated by video, and meetings or telephone conversations with a genetic counselor/study professional.

This is an investigational study. About 800 people will be offered genetic testing. This study is being performed only at MD Anderson.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Genetic Counseling

Detailed Description

Participants will receive pre-test genetic counseling in one of three ways: (1) in person at MD Anderson; (2) by telephone with an MD Anderson Genetic Counselor/study professional; (3) with a local Genetic Counselor in conference with the MD Anderson Genetic Counselor/study professional. After receiving pre-test genetic counseling, participants will be given the opportunity to schedule a submission of a small sample of blood (about 6 tablespoons) for genetic testing for p53. You may have this blood test repeated if there are any problems in the lab. The study doctor will discuss this with you.

Participants who submit a sample may choose to see a genetic counselor/study professional in person or schedule a phone conversation to receive the results of the genetic test. Genetic counseling may take place at MD Anderson at no cost. Participants may wish to have counseling close to their home, though they then are responsible for the cost of the counseling. If, after talking to the counselor/study professional, the participant wants to know the results of the test, he or she will be told. A participant will be given more counseling and advice on what other care might be needed and what other actions they should take.

The test results will be kept private. Names will not be used in computer records.

Study Design

Study Type:
Observational
Actual Enrollment :
577 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Transition From Research to Disclosure in Human Genetics
Actual Study Start Date :
May 6, 1999
Actual Primary Completion Date :
Feb 8, 2022
Actual Study Completion Date :
Feb 8, 2022

Arms and Interventions

Arm Intervention/Treatment
Pre-Test Genetic Counseling + Genetic Sample

Behavioral: Genetic Counseling
Genetic counseling conducted in person, by telephone with an M. D. Anderson Genetic Counselor, or with a local Genetic Counselor in conference with the M. D. Anderson Genetic Counselor.

Outcome Measures

Primary Outcome Measures

  1. Number of Participants Received Pre-test Genetic Counseling [10 Years]

Secondary Outcome Measures

  1. Number of participants completing genetic testing for p53 [Baseline to time of follow-up (2 weeks, 6, and 12 months)]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

2.0 Genetic testing

Members of families who have participated in the p53 project through Dr. Strong's lab are eligible, via protocol P90-001. There are at least 145 kindreds including at least 800 participants living who may be at risk of carrying a p53 germline mutation. The participants must provide an informed consent and be 18 years or older. We will include English and non-English speaking participants. For non-English speaking participants to be recruited, the consent documents has been translated into the language of the target population in accordance with the IRB procedures.

2.1 Parents Attitudes toward testing children at risk for TP53 mutations

For the survey portion of this study, we will invite individuals who 1) are already enrolled in the P90-001 study), 2) have been known to carry a germline p53 mutation, and 3) have children who are less than 27 years old. Patients who agree to enroll in the survey portion of the study will be presented with a consent statement and a printed copy of the survey along with a postage-paid envelope which they can return (either by mail or in person) at their convenience.

2.2 Psychosocial impact of participating in LFS screening

  1. Adults who have undergone genetic testing and have a confirmed p53 mutation

  2. Adults participating in LFS screening program

Exclusion Criteria:

N/A

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Texas MD Anderson Cancer Center Houston Texas United States 77030

Sponsors and Collaborators

  • M.D. Anderson Cancer Center

Investigators

  • Principal Investigator: Louise C. Strong, MD, M.D. Anderson Cancer Center

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT00505466
Other Study ID Numbers:
  • BS99-038
First Posted:
Jul 23, 2007
Last Update Posted:
Mar 4, 2022
Last Verified:
Mar 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by M.D. Anderson Cancer Center

Study Results

No Results Posted as of Mar 4, 2022